HSIC vs IOVA
Henry Schein vs Iovance Biotherapeutics, Inc. — AI-powered side-by-side comparison
VS
IOVA
Iovance Biotherapeutics, Inc.
67
Buy
| Metric | HSIC | IOVA |
|---|
| AI Score |
67
|
67
|
| Price |
$89.16
|
$6.49
|
| P/E Ratio |
25.77×
|
-9.27×
|
| ROE |
12.3%
|
-56.0%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
30.3%
|
116.3%
|
| Debt / Equity |
1.21×
|
0.06×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
59.4
|
79.2
|
| Beta |
0.808
|
0.701
|
| Expected Upside |
+0.8%
|
—
|
AI Committee View
Current Innellis committee reasoning for HSIC versus IOVA.
The committee scores are tied.
HSIC and IOVA both score 67/100.
HSIC Committee View
75% agreement
4 analysts
The primary driver is vix regime is low -- calm backdrop supports risk-taking. The main limiting factor is growth rate is decelerating quarter over quarter -- the trend line matters more than the level. The committee is constructive but not yet at full conviction.
Bull Case
- 4 consecutive earnings beats -- consistent execution — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
IOVA Committee View
67% agreement
6 analysts
The primary driver is revenue growing 34.5% yoy -- genuine top-line momentum. The main limiting factor is roe of only -40.5% -- cheap may mean cheap for a reason. The committee is constructive but not yet at full conviction.
Bull Case
- Revenue growing 34.5% YoY -- genuine top-line momentum — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- ROE of only -40.5% -- cheap may mean cheap for a reason — Value
- RSI at 79 is in overbought territory — Technical
- Weekly RSI at 75 -- overbought on the larger timeframe too — Technical